Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLLT1 | Q03111 | 3/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2067903 | 0.99 | MLLT1 (0.43) | MLLT1HCRTR1HCRTR2DGAT1 | |
| SCHEMBL2068362 | 0.91 | LMNA (0.42) | MLLT1HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL2069386 | 0.91 | LMNA (0.41) | MLLT1HCRTR1HCRTR2 | |
| SCHEMBL2068163 | 0.90 | LMNA (0.44) | MLLT1HCRTR1HCRTR2 | |
| Hydrochloric Acid SCHEMBL2067258 | 0.90 | LMNA (0.44) | MLLT1HCRTR1HCRTR2 | |
| SCHEMBL2068584 | 0.90 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL2066872 | 0.90 | MLLT1 (0.45) | MLLT1 | |
| Hydrochloric Acid SCHEMBL2069179 | 0.89 | MLLT1 (0.45) | MLLT1 | |
| Hydrochloric Acid SCHEMBL2069174 | 0.89 | SMN1; SMN2 (0.45) | — | |
| SCHEMBL2066460 | 0.88 | EPHX2 (0.47) | MLLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170860-B9 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2017-02-22 | — | — | EP | disclosed |
| EP-2170860-B1 | BENZIMIDAZOLE DERIVATIVES | PFIZER (US) | 2016-11-02 | — | — | EP | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431597-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2012-06-21 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148401-B2 | Benzimidazole derivatives | PFIZER INC. (US) | 2012-04-03 | — | — | US | disclosed |
| EP-2170860-A2 | BENZIMIDAZOLE DERIVATIVES | Pfizer Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009004427-A2 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005416-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | MLLT1 1364/4885HCRTR1 3914/4885HCRTR2 4470/4885 |
| US-20120157495-A1 | BENZIMIDAZOLE DERIVATIVES | BOD1L1, H1-3, BRIX1 | MLLT1 1364/4885HCRTR1 3914/4885HCRTR2 4470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.